LEAF-1703

LEAF-1703 is a small molecule anticancer drug candidate developed by L.E.A.F. Pharmaceuticals. It acts as an inhibitor of thymidylate synthase (TYMS), a key enzyme involved in DNA synthesis and repair. By inhibiting TYMS, LEAF-1703 disrupts the serine-glycine one-carbon metabolism pathway, which is often dysregulated in cancer cells and the tumor microenvironment. This mechanism aims to counteract tumor-mediated metabolic dysregulation associated with various cancers and potentially modulate immune responses within the tumor microenvironment. The drug has been investigated for use in several solid tumors, including breast cancer, non-small cell lung cancer, and ovarian cancer[1][3][4][6].